Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997-2011

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bontell, Irene ^a   Häggblom, Amanda ^a   Bratt, Göran ^b   Albert, Jan ^a,c   Sönnerborg, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; RISK ASSESSMENT; SWEDEN; TREND STUDY; VIRUS DETECTION; VIRUS GENOME; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; SWEDEN;

EID: 84875295556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059337     Document Type: Article

References (11)

1. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
2. Tamalet C, Fantini J, Tourres C, Yahi N, (2003) Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17: 2383-2388.
3. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, et al. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393-1401.
4. Pillay D, Green H, Matthias R, Dunn D, Phillips A, et al. (2005) Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 192: 967-973.
5. Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, et al. (2007) Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 12: 835-839.
6. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, et al. (2008) The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 5: 12.
7. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, et al. (2008) Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 198: 51-58.
8. Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, et al. (2009) Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals. J Clin Virol 44: 190-194.
9. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB, (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000.
10. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.Kall.
11. von Wyl V, Yerly S, Boni J, Shah C, Cellerai C, et al. (2012) Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 54: 131-140.